EP2559431A1 — Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
Assigned to Ratiopharm GmbH · Expires 2013-02-20 · 13y expired
What this patent protects
The present invention relates to a pharmaceutical composition having a density of more than 1.55g/cm 3 in the form a tablet comprising 4-[4-[[4-chloro-3-(tifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide or a pharmaceutically acceptable salt thereof a…
USPTO Abstract
The present invention relates to a pharmaceutical composition having a density of more than 1.55g/cm 3 in the form a tablet comprising 4-[4-[[4-chloro-3-(tifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide or a pharmaceutically acceptable salt thereof as active agent and at least one pharmaceutically acceptable excipient as well as a method of manufacturing such pharmaceutical composition.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.